Low profile transcatheter aortic valve implant
Ended Project Grant Awarded Last action
- Award ID
- R43HL174201
- Recipient
-
3DT Holdings, LLC UEI E527XPXM1CJ7
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $497,401
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- Transcatheter aortic valve replacement (tavr) is gradually becoming an essential alternative to surgical aortic valve replacement (savr) for patients with severe aortic stenosis (as) at high or prohibitive surgical risk. The published partner 3 and evolut low-risk trials have recently demonstrated that tavr can be considered in low-risk patients. However, the long-term durability of transcatheter prosthetic valves has become a major concern nowadays, especially for young patients with greater life expectancy. Although increased efficacy and safety of the current leading tavr valves (e.g., medtronic corevalve and edwards sapien) have been reported lately, tissue valve dysfunction and failure remain the limiting factors for the long-term outcome of tavr. Furthermore, the application of those tavr valves is limited to certain patients due to the use of the relatively large delivery system (typically 14-16 FR. Size). There is a substantial clinical desire for a lower-profile delivery system since IT accommodates a greater population of patients with peripheral artery disease or small arteries and reduces the risk of vascular complications following transfemoral tavr. IT is well known that calcification plays a major role in the failure of bioprostheses and other tissue heart valve substitutes. Mechanical stress imposed on the leaflets contributes to the growth of calcium crystals and collagen fibers' disruption, which induces thrombosis, calcification, and early valve failure. Therefore, a superior biomaterial with appropriate mechanical (low stress) and structural (thickness) properties may provide a solution for prolongation of transcatheter valve durability and size reduction of delivery system. Our group has previously verified that swine and bovine pulmonary visceral pleura (PVP) are highly elastic and much thinner (~1/3 of the thickness) than bovine pericardial tissue typically used for the current tavr valves. The larger compliance and smaller thickness of PVP make IT possible to become a more durable valve leaflet and to be delivered with a lower profile delivery system (
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $497,401 |
Quick answers
Who received award R43HL174201?
R43HL174201 was awarded to 3DT Holdings, LLC by National Heart Lung and Blood Institute (National Institutes of Health) on May 1, 2024.
How much is award R43HL174201 worth?
$497,401 has been obligated on R43HL174201.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award